Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses how patients are responding to using biosimilars.
Transcript
Most patients are not necessarily aware of biosimilars yet. It's still very new. It's still new for the practitioners. When it's explained in a fashion that they can understand, they've been overwhelmingly enthusiastic and supportive about it.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.